Viridian Therapeutics, Inc. VRDN Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s payment-in-kind interest?
- Viridian Therapeutics, Inc. (VRDN) reported payment-in-kind interest of $2.34M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s payment-in-kind interest changed year-over-year?
- Viridian Therapeutics, Inc.'s payment-in-kind interest increased by 2175.7% year-over-year, from $103K to $2.34M.
- What does payment-in-kind interest mean?
- This represents interest expense that is settled through the issuance of additional debt or equity instruments rather than cash payments. It highlights the company's use of non-cash financing mechanisms to manage interest obligations while preserving liquidity. Investors monitor this to understand the true cost of debt and potential future dilution or increased debt burden.